source
- Acadia’s Alzheimer’s psychosis drug misses Phase 2 goals, but moves to revised Phase 3Acadia Pharmaceuticals announced that its experimental treatment for psychosis linked to Alzheimer’s disease failed to meet the primary endpoints in a Phase 2 trial. The company said the data stil…
- Acadia’s Alzheimer’s psychosis drug misses primary goal but advances on secondary dataAcadia Pharmaceuticals reported that its investigational drug remlifanserin failed to meet the primary endpoint in the Phase 2 portion of the RADIANT trial for Alzheimer’s disease psychosis. The t…